By blocking the activity of these kinases, JAK inhibitors can simultaneously interfere with the signaling of multiple proinflammatory cytokines, including IL-4, IL-13, IL-31, IL-17, IL-22, and interferon-gamma, which are involved in AD (16). This evidence concerns the gene IL31 and Alzheimer disease.